KHTRF (Knight Therapeutics) Cyclically Adjusted FCF per Share: $-0.05 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KHTRF Knight Therapeutics Inc KHTRF
71 GF Score
Price $6.96
GF Value $6.16
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Cyclically Adjusted FCF per Share?

Knight Therapeutics KHTRF -1.62% 71 Cyclically Adjusted FCF per Share is $-0.05 as of Mar. 2026. GuruFocus rates KHTRF with a GF Score™ of 71/100 and a GF Value™ of $6.16 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Knight Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.245. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-23), Knight Therapeutics's current stock price is $6.96. Knight Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.05. Knight Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Knight Therapeutics  (OTCPK:KHTRF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Knight Therapeutics Cyclically Adjusted FCF per Share Related Terms


Knight Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Cyclically Adjusted FCF per Share Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.09 -0.08 -0.07

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.09 -0.09 -0.07 -0.05

KHTRF vs ZTS, UTHR: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


KHTRF
71GF Score
Knight Therapeutics Inc KHTRF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Knight Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.245/132.2623*132.2623
=0.245

Current CPI (Mar. 2026) = 132.2623.

Knight Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.021 102.002 0.027
201609 0.023 101.765 0.030
201612 -0.021 101.449 -0.027
201703 0.022 102.634 0.028
201706 0.018 103.029 0.023
201709 0.061 103.345 0.078
201712 0.028 103.345 0.036
201803 0.021 105.004 0.026
201806 0.021 105.557 0.026
201809 -0.107 105.636 -0.134
201812 0.013 105.399 0.016
201903 -0.059 106.979 -0.073
201906 0.013 107.690 0.016
201909 0.020 107.611 0.025
201912 0.038 107.769 0.047
202003 -0.126 107.927 -0.154
202006 -0.018 108.401 -0.022
202009 -0.060 108.164 -0.073
202012 0.005 108.559 0.006
202103 0.101 110.298 0.121
202106 -1.336 111.720 -1.582
202109 0.051 112.905 0.060
202112 0.012 113.774 0.014
202203 0.085 117.646 0.096
202206 -0.034 120.806 -0.037
202209 0.073 120.648 0.080
202212 0.000 120.964 0.000
202303 -0.023 122.702 -0.025
202306 -0.011 124.203 -0.012
202309 0.103 125.230 0.109
202312 0.117 125.072 0.124
202403 0.145 126.258 0.152
202406 -0.133 127.522 -0.138
202409 0.022 127.285 0.023
202412 0.003 127.364 0.003
202503 0.000 129.181 0.000
202506 -0.036 129.892 -0.037
202509 0.053 130.287 0.054
202512 0.239 130.366 0.242
202603 0.245 132.262 0.245

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.05 mean?
Knight Therapeutics (KHTRF) has a Cyclically Adjusted FCF per Share of $-0.05 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Cyclically Adjusted FCF per Share too high?
Knight Therapeutics' current Cyclically Adjusted FCF per Share is $-0.05. Overall, Knight Therapeutics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Knight Therapeutics' Cyclically Adjusted FCF per Share of $-0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Cyclically Adjusted FCF per Share is $-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (KHTRF) is currently considered Modestly Overvalued. The stock's GF Value™ is $6.16, compared to a current price of $6.96 — trading 13% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.05. Knight Therapeutics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Knight Therapeutics (KHTRF), the current Cyclically Adjusted FCF per Share is $-0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (KHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of $6.96 is trading 13% above its estimated GF Value™ of $6.16. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for KHTRF:

  • Cyclically Adjusted FCF per Share: $-0.05
  • GF Value™: $6.16 vs. price of $6.96 (13% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the KHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges GUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
71GF Score

Get the complete analysis for KHTRF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.96
Price
$6.16
GF Value